Retraction
Trastuzumab-modified DM1-loaded nanoparticles for HER2+ breast cancer treatment: an in vitro and in vivo study
Paper Information
Record ID:
24970
Author(s):
Publication Date:
October 25, 2017
Retraction Date:
January 11, 2021
(4.9 years years ago)
Subjects:
Institutions:
- Bozhou People's Hospital Affiliated to Medical College, Anhui University of Science & Technology, Bozhou, China
- Medical College, Anhui University of Science & Technology, Huainan, China
- Huainan First People's Hospital and First Affiliated Hospital of Medical College, Anhui University of Science & Technology, Huainan, China
Country:
🇨🇳 ChinaArticle Type:
Publisher:
Taylor and Francis
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1080/21691401.2020.1836888Citations (13)
13
Total Citations4
Post-Retraction(30.8%)
9
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
0
Within 30 days
4
Within 1 year
0
After 2+ years
355
Days since retraction (latest)
Nanotechnology in the development of small and large molecule tyrosine kinase inhibitors and immunotherapy for the treatment of HER2-positive breast cancer.
Victor Ejigah, Bharathi Mandala, Emmanuel O. Akala
PubMed
Published: Jan 2022
355 days after retraction
Receptor-Mediated Targeted Delivery of Surface-ModifiedNanomedicine in Breast Cancer: Recent Update and Challenges
Md. Rizwanullah, Mohammad Zaki Ahmad, Mohammed M. Ghoneim et al. (9 authors)
Pharmaceutics
Open Access
Published: Nov 2021
35 citations
35 citations
322 days after retraction
Paper citing Trastuzumab-modified DM1-loaded nanoparticles for ...
Unknown Authors
Unknown Journal
Published: May 2021
110 days after retraction
Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression
Dengyang Zhang, Yao Guo, Yuming Zhao et al. (16 authors)
Microbial Cell Factories
Open Access
Published: Mar 2021
4 citations
4 citations
58 days after retraction
Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy
Colin T. Huang, Xin Guo, Cyril Bařinka et al. (9 authors)
Molecular Pharmaceutics
Open Access
Published: Aug 2020
26 citations
26 citations
147 days before retraction
Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer
Shivaprasad Gadag, Shristi Sinha, Yogendra Nayak et al. (5 authors)
Pharmaceutics
Open Access
Published: Jun 2020
35 citations
35 citations
217 days before retraction
Biologicals to direct nanotherapeutics towards HER2-positive breast cancers
Gautam Kumar, Krishnadas Nandakumar, Srinivas Mutalik et al. (4 authors)
Nanomedicine Nanotechnology Biology and Medicine
Published: Apr 2020
19 citations
19 citations
279 days before retraction
Lanthanide-Doped SPIONs Bioconjugation with Trastuzumab for Potential Multimodal Anticancer Activity and Magnetic Hyperthermia
Weronika Gawęda, Magdalena Osial, Michał Żuk et al. (6 authors)
Nanomaterials
Open Access
Published: Feb 2020
33 citations
33 citations
338 days before retraction
Zein nanoparticles as nontoxic delivery system for maytansine in the treatment of non-small cell lung cancer
Xianglong Yu, Huichao Wu, Haiyan Hu et al. (9 authors)
Drug Delivery
Open Access
Published: Dec 2019
70 citations
70 citations
384 days before retraction
HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted Treatment of Ovarian Tumor
Lin Ding, Wenxing Gu, Yifan Zhang et al. (7 authors)
Biomacromolecules
Open Access
Published: Sep 2019
16 citations
16 citations
487 days before retraction
Recent advances of nanotechnology for the delivery of anticancer drugs for breast cancer treatment
Phuong Tran, Sang‐Eun Lee, Donghyun Kim et al. (5 authors)
Journal of Pharmaceutical Investigation
Published: Aug 2019
110 citations
110 citations
504 days before retraction
Drug Combinations in Breast Cancer Therapy
Funmilola A. Fisusi, Emmanuel O. Akala
Pharmaceutical Nanotechnology
Open Access
Published: Jan 2019
387 citations
387 citations
720 days before retraction
Carvacrol nanoemulsion evokes cell cycle arrest, apoptosis induction and autophagy inhibition in doxorubicin resistant-A549 cell line
Imran Khan, Ashutosh Bahuguna, Monika Bhardwaj et al. (5 authors)
Artificial Cells Nanomedicine and Biotechnology
Open Access
Published: Feb 2018
43 citations
43 citations
1070 days before retraction
Quick Stats
Total Citations:
13
Years Since Retraction:
4.9 years
Open Access:
Yes
Last Checked:
Jul 24, 2025